Emerging treatment options for patients with recurrent advanced thymic epithelial tumors.

ABSTRACT: The purpose of this review article is to review recent advances in the treatment of advanced thymic epithelial tumors. These tumors are generally responsive to cytotoxic combination chemotherapy in the first-line setting. While newer agents have shown efficacy in the salvage setting, there is no one standard approach. A multitude of targeted agents have shown promise generally in case reports, though as of yet, nothing has shown consistent benefit. Because of the rarity of thymic epithelial tumors, clinical trial enrollment is difficult but nevertheless essential.

SUBMITTER: Evans TL 

PROVIDER: S-EPMC3439855 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature